Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ANCN Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Anchiano Therapeutics (ANCN) Competitors

Anchiano Therapeutics logo
Compare

ANCN vs. NBRV, LITS, ATNM, TAOX, and ADXS

Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Nabriva Therapeutics (NBRV), Lite Strategy (LITS), Actinium Pharmaceuticals (ATNM), Synaptogenix (TAOX), and Ayala Pharmaceuticals (ADXS).

How does Anchiano Therapeutics compare to Nabriva Therapeutics?

Anchiano Therapeutics (NASDAQ:ANCN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

9.1% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Anchiano Therapeutics' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company Overall Sentiment
Anchiano Therapeutics Neutral
Nabriva Therapeutics Neutral

Anchiano Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46N/A
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A

Anchiano Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Anchiano Therapeutics' return on equity of 36.08% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anchiano TherapeuticsN/A 36.08% 27.40%
Nabriva Therapeutics -148.11%-365.53%-135.81%

Anchiano Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Summary

Anchiano Therapeutics beats Nabriva Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Anchiano Therapeutics compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 1.6% of Lite Strategy shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anchiano Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Anchiano Therapeutics' return on equity of 36.08% beat Lite Strategy's return on equity.

Company Net Margins Return on Equity Return on Assets
Lite StrategyN/A -68.86% -67.48%
Anchiano Therapeutics N/A 36.08%27.40%

Lite Strategy has higher revenue and earnings than Anchiano Therapeutics. Lite Strategy is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lite Strategy$65.30M0.63-$15.94M-$1.33N/A
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46N/A

Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

In the previous week, Lite Strategy's average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score.

Company Overall Sentiment
Lite Strategy Neutral
Anchiano Therapeutics Neutral

Summary

Lite Strategy and Anchiano Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Anchiano Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Actinium Pharmaceuticals presently has a consensus target price of $4.50, suggesting a potential upside of 257.14%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than Anchiano Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Anchiano Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Anchiano Therapeutics' return on equity of 36.08% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Anchiano Therapeutics N/A 36.08%27.40%

Anchiano Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$90K439.25-$48.82M-$1.08N/A
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46N/A

Actinium Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score.

Company Overall Sentiment
Actinium Pharmaceuticals Neutral
Anchiano Therapeutics Neutral

Summary

Actinium Pharmaceuticals and Anchiano Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Anchiano Therapeutics compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score.

Company Overall Sentiment
Synaptogenix Neutral
Anchiano Therapeutics Neutral

Synaptogenix has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anchiano Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Anchiano Therapeutics has lower revenue, but higher earnings than Synaptogenix. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synaptogenix$300K140.69-$28.74M-$17.14N/A
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46N/A

Anchiano Therapeutics' return on equity of 36.08% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -193.08% -144.93%
Anchiano Therapeutics N/A 36.08%27.40%

Summary

Anchiano Therapeutics beats Synaptogenix on 6 of the 10 factors compared between the two stocks.

How does Anchiano Therapeutics compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Anchiano Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.24M11.05-$48.07M-$5.02N/A
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46N/A

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score.

Company Overall Sentiment
Ayala Pharmaceuticals Neutral
Anchiano Therapeutics Neutral

Anchiano Therapeutics' return on equity of 36.08% beat Ayala Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ayala PharmaceuticalsN/A N/A N/A
Anchiano Therapeutics N/A 36.08%27.40%

Summary

Anchiano Therapeutics beats Ayala Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Get Anchiano Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANCN vs. The Competition

Export
MetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$12.69M$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio11.401.7129.2527.07
Price / SalesN/A120.63504.6873.47
Price / CashN/A20.0743.3053.90
Price / Book0.857.609.676.69
Net Income-$27.12M-$4.80M$3.55B$332.64M

Anchiano Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANCN
Anchiano Therapeutics
N/A$1.71
+1.8%		N/AN/A$12.69MN/A11.4016
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59MN/A70
LITS
Lite Strategy
0.0663 of 5 stars		$1.15
+0.9%		N/AN/A$41.81M$65.30MN/A100
ATNM
Actinium Pharmaceuticals
2.1505 of 5 stars		$1.17
-1.7%		$4.50
+284.6%		N/A$36.71M$90KN/A30
TAOX
Synaptogenix
N/A$4.83
-4.4%		N/AN/A$36.08M$300KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ANCN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel